BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/20/2025 8:05:20 AM | Browse: 28 | Download: 118
 |
Received |
|
2025-02-08 06:06 |
|
Peer-Review Started |
|
2025-02-08 06:06 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-03-13 09:55 |
|
Revised |
|
2025-03-26 20:12 |
|
Second Decision |
|
2025-05-16 02:51 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-05-16 10:46 |
|
Articles in Press |
|
2025-05-16 10:46 |
|
Publication Fee Transferred |
|
2025-03-29 08:31 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-06-09 08:31 |
|
Publish the Manuscript Online |
|
2025-06-20 08:05 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Advances in neoadjuvant therapy for pancreatic cancer: Current trends and future directions
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shi-Tao Wu, Li Zhu, Xiao-Ling Feng, Li Yang, Guo-Wei Chen, Yan Jiang, Ting-Fang Huang, Hao-Yu Wang and Fang Li |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fang Li, MD, PhD, Department of General Surgery, Chongqing General Hospital, No. 118 Xingguang Avenue, Liangjiang New District, Chongqing 401147, China. leef123456@163.com |
| Key Words |
Neoadjuvant therapy; Pancreatic cancer; Surgical outcomes; Imaging techniques; Biomarkers |
| Core Tip |
This review highlights the transformative role of neoadjuvant therapy in managing pancreatic ductal adenocarcinoma (PDAC), emphasizing its benefits in improving resectability, enhancing margin-negative resection (R0) rates, and addressing micrometastatic disease. The integration of advanced imaging modalities, such as positron emission tomography/computed tomography with 18F-fluorodeoxyglucose, and biomarkers like carbohydrate antigen 19-9 enables personalized treatment strategies and better surgical planning. By synthesizing recent evidence, the study underscores the critical importance of multimodal approaches, tailored regimens, and emerging therapies in optimizing outcomes for patients with resectable and borderline resectable PDAC. |
| Publish Date |
2025-06-20 08:05 |
| Citation |
<p>Wu ST, Zhu L, Feng XL, Yang L, Chen GW, Jiang Y, Huang TF, Wang HY, Li F. Advances in neoadjuvant therapy for pancreatic cancer: Current trends and future directions. <i>World J Clin Oncol</i> 2025; 16(6): 105849</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i6/105849.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i6.105849 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
